Aflazin (hibiscus extract) capsules 200 mg. №30

Description

Composition

active substance: 1 capsule contains 200 mg of dry hibiscus extract (hibisci extractum siccum);

excipients : lactose monohydrate, povidone;

composition of hard gelatin capsule : gelatin, titanium dioxide (E 171), tartrazine (E 102), amaranth (E 123), erythrosine (E 127), patented blue V (E 131).

Pharmacotherapeutic group

Used in urology. ATX code G04B X.

Pharmacodynamics

Patented hibiscus extract is a source of organic acids (citric, oxysuccinic, pyrocatechinic, hibiscus), vitamins, polysaccharides, bioflavonoids, which determine the bacteriostatic effect of the drug Aflazin against most pathogens of urinary tract infections (Staphylococcus spp., Streptococcus spp., Enterococcus faecalis, Escherichia coli) , Enterobacter spp. Candida spp.). It has anti-inflammatory, anti-edematous properties, exhibits an anti-adhesive effect, which prevents the adhesion (sticking) of microorganisms to the walls of the urinary tract, their development and reproduction. Prevents the development of dysuric phenomena.

Indication

• As part of complex therapy for acute and chronic infections of the bladder (cystitis) and kidneys (pyelonephritis), for asymptomatic bacteriuria, including in pregnant women.
• Chronic non-infectious kidney diseases (glomerulonephritis, interstitial nephritis), prevention of urinary tract infections, including after instrumental interventions (endoscopic, X-ray and gynecological examinations).
• Prevention of formation of urinary stones, including after their removal.

Contraindications of Aflazin

• Individual sensitivity to any of the components of the drug.

Dosage and Administration of Aflazin

Adults and children over 12 years of age should use 1 capsule 2 times a day, regardless of meals. Children aged 6 to 12 years – 1 capsule once a day. The duration of use is set by the doctor individually depending on the severity of the disease. The recommended duration of use for acute inflammation of the urinary tract and exacerbation of chronic diseases is 4–6 weeks. The recommended course of application for preventive purposes is 2–4 weeks.

Children.

The drug can be used by children aged 6 years and older.

Since the medicine contains lactose, it should not be used in patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.